India's public sector pharma: flogging a dead horse?
This article was originally published in Scrip
Stop wasting public funds; privatize or perish; and the government has no business being in business, especially if the business is badly run. These appear to be common refrains of some experts on India's struggling public sector pharmaceutical firms – the bulk of which are sick.
You may also be interested in...
India's apex pricing authority has specified the modalities for firms wanting to stop supplies of certain essential drugs in the country. Industry, though, claims that the regulator may have exceeded its remit and underscores how a lopsided pricing policy approach can lead to potential shortages.
Wockhardt has received approvals in India for two novel broad spectrum antibiotics with "advantageous" safety features over older MRSA drugs and the firm hopes to take them to other emerging markets as well, with China on the radar.
2019 saw Indian companies advance innovation efforts and build and expand their specialty portfolios and biosimilars businesses. But manufacturing compliance issues weighed down several firms while on another front charges against the Singh brothers of Ranbaxy escalated.